Journals / Retina-Vitreus / 2020 / Cilt: 29 - Sayı: 4

Brolucizumab: What’s new and newer about it?

Pages
287–291
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug approved for use.
📊
Key Findings & Data:The aim of this review is to review the HAWK/HARRIER clinical trials, examine post-marketing experience with the drug, and evaluate the packaging/procedural differences with brolucizumab.
💡
Conclusion & Impact:Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug approved for use. The aim of this review is to review the HAWK/HARRIER clinical trials, examine post-marketing experience with the drug, and evaluate the packaging/procedural differences with brolucizumab. Brolucizumab is a more potent and longer lasting anti-VEGF agent, and is an important agent that may be used in the treatment of neovascular age-related macular degeneration. Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of.

🔖

Cite This Article

ANDERSON, W. J., AKDUMAN, L. (2020). Brolucizumab: What’s new and newer about it?. Retina-Vitreus, Cilt: 29 - Sayı: 4, 287–291. https://ajindex.com/articles/304786

References (10)

  1. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72-84
  2. Avaylon J, Lee S, Gallemore RP. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration. Int Med Case Rep J. 2020;13:145-52
  3. Witkin AJ, Hahn P, Murray TG, et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4:269-79. 4. https://www.brolucizumab.info/post-marketing-data. Accessed September 30th, 2020. 5. https://www.brolucizumab.info/sites/brolucizumab_info/fi les/2020-07/ASRS_SRC_report.pdf. Accessed August 31st, 2020. 6. https://www.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd. Accessed September 30th, 2020
  4. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98
  5. Gianniou C, Dirani A, Jang L, Mantel I. Refractory Intraretinal or Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Intravitreal Ranizubimab: Functional and Structural Outcome. Retina. 2015;35:1195-201
  6. Guymer RH, Markey CM, McAllister IL, et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2019;126:723-34
  7. Hsu J, Patel SN, Wolfe JD, et al. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2020
  8. Byeon SH, Kwon OW, Song JH, Kim SE, Park YS. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):35-42
  9. Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42:103-29
  10. Bontzos G, Bagheri S, Ioanidi L, et al. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2019.